Actuate Therapeutics (ACTU) announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The company intends to use the net proceeds from the proposed offering for working capital and general corporate purposes. Lucid Capital Markets is acting as sole book-running manager for the offering.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACTU:
- Actuate Therapeutics files $250M mixed securities shelf
- Actuate Therapeutics initiated with a Buy at B. Riley
- Actuate Therapeutics, Inc.: Strategic Regulatory Advances and Promising Clinical Data Drive Buy Rating
- Actuate, Incyte, University of Pittsburgh collaborate on elraglusib trial
- Actuate Therapeutics files to sell 1.33M shares of common stock for holders